查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010059

银屑病治疗市场：2026-2032年全球市场预测（按药物类别、给药途径、银屑病类型、患者人口统计特征、分销管道和治疗环境划分）

Psoriasis Drugs Market by Drug Class, Route Of Administration, Psoriasis Type, Patient Type, Distribution Channel, Treatment Setting - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，干癣治疗市场价值将达到 121.8 亿美元，到 2026 年将成长至 135.9 亿美元，到 2032 年将达到 276.3 亿美元，年复合成长率为 12.41%。

主要市场统计数据
基准年 2025 121.8亿美元
预计年份：2026年 135.9亿美元
预测年份 2032 276.3亿美元
复合年增长率 (%) 12.41%

权威概述了当前银屑病治疗方法、制度压力以及影响银屑病治疗发展和商业化的策略挑战。

目前银屑病治疗的特点是科学的快速发展和商业性趋势的不断演变。标靶生物製药和口服小分子化合物的进步正在拓展治疗选择，并提高了人们对疗效、持续缓解和患者便利性的期望。同时，支付方的严格审查、日益复杂的供应链以及不断变化的监管要求，都要求製药公司和医疗机构调整其营运和商业性策略。因此，相关人员必须权衡临床潜力与实际考量，例如生产规模化、真实世界安全性监测以及如何传递差异化价值。

临床、监管和商业性方面的变革正在重新定义银屑病治疗的差异化、获取途径和价值主张。

科学突破、监管进步以及患者对个人化医疗的期望正在重塑银屑病治疗的模式。针对白细胞介素路径的生物製药和口服标靶抑制剂正在加速治疗方案的差异化，引导临床医师考虑针对特定机制的治疗方案，以惠及以往传统治疗方法难以涵盖的患者亚群。同时，法律规范正采用更有效率的策略，基于可靠的生物标记和真实世界数据，核准和扩展新药的适应症，使其能够快速应用于临床实践。

到 2020 年代中期，不断变化的美国关税措施对干癣治疗的供应链、筹资策略和市场进入趋势的累积影响。

美国近期对药品原料和成品的关税结构调整，为银屑病治疗药物的全球供应链带来了新的复杂性。活性成分、生物製药和辅助材料的关税变化可能会增加依赖国际采购的製造商的接收成本，促使他们重新评估供应商组合和物流策略。为此，各组织正在探索近岸外包、双重采购和合约避险等措施，以确保原料供应稳定并保障生产的连续性。

将治疗领域、给药途径、患者表型、人口统计特征、分销管道和医疗保健环境与策略重点联繫起来的基于全面细分的洞察。

深入了解银屑病市场细分如何影响产品开发、临床定位和商业性策略至关重要。治疗分类将药物分为生物製药和小分子药物。生物製药包括标靶药物，如IL-17抑制剂、IL-23抑制剂和TNF抑制剂；而小分子药物则包括JAK抑制剂和PDE4抑制剂。每类药物在疗效、安全性、给药途径和生产製造方面都有其独特的考量因素，这些因素会影响临床医师在选择药物和健保报销方面的决策。

影响美洲、欧洲、中东和非洲以及亚太地区监管策略、准入途径和商业化方法的区域特定趋势。

区域趋势持续影响美洲、欧洲、中东和非洲以及亚太地区的研发重点、监管规划和商业策略。在美洲，成熟的法规环境和完善的专业医疗网络推动创新生物製药和先进支援服务的快速普及，而与支付方的谈判以及纳入处方药目录仍然至关重要。在该地区，临床医生网络和患者权益组织往往推动着高效治疗方法的早期应用，而报销机制则要求明确证明其长期疗效。

公司层面的干癣治疗策略，强调临床差异化、生产弹性、符合支付方需求的证据产生、以病人为中心的商业化。

在干癣治疗领域，领先的製药和生物技术公司正面临许多复杂因素的挑战：临床差异化、生产要求以及支付者的参与。成熟的生物製药研发公司正在加大对下一代白细胞介素标靶药物和生命週期管理的投资，而较小的生物技术公司则专注于创新的作用机制和基于生物标记的适应症。同时，专业製药公司正在推广口服小分子药物和联合治疗，这些药物和疗法优先考虑给药的便利性，以满足希望避免注射的患者亚群。儘管这些公司的情况各不相同，但它们的战略重点都指向同一个目标：透过给药和支持方面的创新，证明药物的持续疗效，提高安全性，并优化患者体验。

为行业领导者制定可操作的策略重点，以协调临床差异化、製造韧性、支付方参与和以患者为中心的商业化，从而实现可持续的成功。

产业领导企业应采取多管齐下的策略，平衡科研投入、营运效率和支付方参与，以在不断发展的银屑病治疗领域取得成功。优先发展那些透过清晰的作用机制实现差异化，并结合可靠的安全性和可持续性终点的研发项目；设计能够收集患者报告结果和真实世界疗效数据的临床试验，以支持全面的价值提案。同时，应投入资源确保生产的柔软性，包括区域生产能力和检验的替代供应商，以降低贸易政策变化带来的风险，并防止临床和商业性供应中断。

本报告的策略和营运结论得到了详细的调查方法支持，包括与主要专家的对话、对二手证据的检验验证以及基于情境的分析。

本研究整合了对一手和二手资料的系统性回顾、专家访谈以及定性分析，以得出严谨而令人信服的见解。主要资讯来源包括对临床意见领袖、支付方、供应链专家和商业高管的访谈，这些访谈提供了有关治疗方法采纳、报销趋势和营运限制的背景资讯。二手研究涵盖了同行评审的临床文献、监管指导文件、上市公司资讯披露以及生产技术参考资料，以支持临床机制、安全性考虑和生产实际情况。

结论强调了整合科学创新、营运韧性、与支付方一致的证据和以病人为中心的服务体系对于实现治疗效果的重要性。

总之，目前银屑病治疗领域蕴藏着巨大的科研机会，但也面临日益复杂的营运与商业挑战。生物製药和标靶小分子化合物的进步提高了治疗标准，但要将这些进步转化为可持续的患者获益，需要製定一项综合策略，整合循证医学证据、生产韧性以及与支付方相符的价值论证。相关人员必须认识到，仅靠临床差异化是不够的，还需要供应链的灵活性来展现长期疗效、以病人为中心的交付机制，以及对真实世界数据（REW）计画的同步投资。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 银屑病治疗市场：依药物类别划分

  • 生物製药
    • IL-17抑制剂
    • IL-23抑制剂
    • TNF抑制剂
  • 小分子药物
    • JAK抑制剂
    • PDE4抑制剂

第九章 银屑病治疗市场：依给药途径划分

  • 注射药物
    • 静脉
    • 皮下
  • 口服
    • 胶囊
    • 悬浮液
    • 药片
  • 外用
    • 奶油
    • 形式
    • 凝胶
    • 软膏

第十章：以银屑病类型分類的干癣治疗市场

  • 红皮病型干癣
  • 水滴状干癣
  • 反向银屑病
  • 指甲银屑病
  • 斑块型干癣
  • 脓疱型干癣
  • 头部银屑病

第十一章：按患者群体分類的银屑病治疗市场

  • 成人
  • 老年人
  • 儿童

第十二章 银屑病治疗市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科药房

第十三章：依治疗环境分類的干癣治疗市场

  • 居家治疗
  • 住院治疗
  • 专业皮肤科诊所

第十四章 银屑病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 银屑病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 银屑病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国银屑病治疗市场

第十八章：中国银屑病治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Dermavant Sciences Ltd.
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • UCB SA
Product Code: MRR-434CCDA051B5

The Psoriasis Drugs Market was valued at USD 12.18 billion in 2025 and is projected to grow to USD 13.59 billion in 2026, with a CAGR of 12.41%, reaching USD 27.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.18 billion
Estimated Year [2026] USD 13.59 billion
Forecast Year [2032] USD 27.63 billion
CAGR (%) 12.41%

An authoritative introduction summarizing the current therapeutic modalities, systemic pressures, and strategic questions shaping psoriasis drug development and commercialization

The psoriasis therapeutics landscape has entered a phase defined by rapid scientific progress and shifting commercial dynamics. Advances in targeted biologic agents and oral small molecules have expanded therapeutic options and raised expectations for improved efficacy, remission durability, and patient convenience. At the same time, payer scrutiny, supply chain complexity, and evolving regulatory expectations require manufacturers and healthcare providers to adapt operational and commercial approaches. Consequently, industry stakeholders must reconcile clinical promise with pragmatic considerations including manufacturing scalability, real-world safety monitoring, and differentiated value communication.

This introduction frames the subsequent analysis by summarizing the current therapeutic modalities, the principal clinical and commercial pressures, and the strategic questions that companies, clinicians, and payers are now confronting. It outlines how therapeutic classification, administration route, patient severity, psoriasis subtype, patient demographics, distribution channels, and treatment settings collectively shape adoption pathways and long-term care models. By situating recent innovations within realistic implementation constraints, this section prepares readers to assess strategic options, anticipate operational bottlenecks, and prioritize investments that will deliver sustained clinical and commercial returns.

Transformative clinical, regulatory, and commercial shifts are converging to redefine therapeutic differentiation, access pathways, and value demonstration in psoriasis care

The psoriasis treatment paradigm is being reshaped by converging scientific breakthroughs, regulatory evolution, and patient expectations for personalized care. Biologics targeting interleukin pathways and orally administered targeted inhibitors have accelerated therapeutic differentiation, leading clinicians to consider mechanism-specific choices for patient subgroups previously underserved by older treatments. Concurrently, regulatory pathways are accommodating more streamlined approval strategies for novel agents and for label expansions based on robust biomarker and real-world evidence, enabling faster clinical integration.

Pharmacoeconomic considerations have gained prominence, compelling manufacturers to demonstrate value through comparative effectiveness, durability, and patient-reported outcomes rather than relying solely on clinical efficacy endpoints. Distribution and delivery innovations, including increased use of specialty pharmacies, home-based administration pathways, and digital adherence supports, are altering how patients engage with treatment regimens. As a result, commercial success increasingly depends on an integrated approach that aligns clinical differentiation with robust evidence of long-term benefit, patient-centric delivery solutions, and payer-aligned value propositions. These transformative shifts are creating both opportunities and heightened competitive pressures across the therapeutic ecosystem.

Cumulative implications of evolving United States tariff measures on psoriasis drug supply chains, sourcing strategies, and commercial access dynamics through mid-decade

Recent policy developments introducing or adjusting United States tariff structures for pharmaceutical inputs and finished products have introduced new layers of complexity into global psoriasis drug supply chains. Tariff changes targeting active pharmaceutical ingredients, biologic components, and ancillary materials have the potential to increase landed costs for manufacturers that rely on international sourcing, prompting reassessments of supplier portfolios and logistics strategies. In response, organizations are evaluating nearshoring, dual-sourcing, and contractual hedges to stabilize input availability and protect production continuity.

Beyond direct cost implications, tariffs can influence the timing of product launches and the sequencing of market access activities by shifting operational priorities toward supply-chain resilience. Clinical trial supply logistics that span borders may require additional customs planning and contingency stock to maintain enrollment schedules. Meanwhile, manufacturers with vertically integrated production or domestic biologics manufacturing capabilities may find strategic advantages in cost predictability and regulatory alignment. Importantly, payers and procurement stakeholders are sensitive to any sustained pricing pressures that could affect formulary dynamics and contracting negotiations, which in turn influences manufacturer strategies for rebates, risk-sharing agreements, and patient support programs.

In summary, tariffs act as a catalyst for broader supply-chain modernization and geographic diversification of manufacturing. Stakeholders are therefore advised to adopt a holistic view that balances near-term operational responses with longer-term investments in manufacturing agility, alternative sourcing, and collaborative agreements that mitigate exposure to trade policy volatility.

Comprehensive segmentation-driven insights linking therapeutic class, administration route, patient phenotype, demographics, distribution channels, and care settings to strategic priorities

A nuanced understanding of how the psoriasis market segments informs product development, clinical positioning, and commercial engagement. Therapeutic classification differentiates between biologic therapies and small-molecule agents; biologics encompass targeted classes such as IL-17 inhibitors, IL-23 inhibitors, and TNF inhibitors, while small molecules include JAK inhibitors and PDE4 inhibitors. Each class carries distinct efficacy, safety, administration, and manufacturing considerations that influence clinician selection and reimbursement discussions.

Route of administration is a critical determinant of patient preference and health-system workflows, spanning injectable, oral, and topical modalities. Injectable formulations are further categorized by intravenous and subcutaneous delivery, each with unique clinical monitoring and administration infrastructure requirements; oral options include capsules, suspensions, and tablets that vary in dosing convenience and pharmacokinetic profiles; topical therapies are formulated as creams, foams, gels, or ointments tailored to lesion characteristics and patient adherence. Patient severity divides the landscape into mild-to-moderate and moderate-to-severe presentations, guiding escalation pathways and eligibility for systemic or biologic therapies.

Psoriasis manifests in clinically distinct subtypes including erythrodermic, guttate, inverse, nail, plaque, pustular, and scalp presentations, and these phenotypes often necessitate differentiated therapeutic strategies and outcome metrics. Patient demographics span adults, geriatric populations, and pediatric cohorts, each with unique safety and dosing considerations that affect labeling, trial design, and market positioning. Distribution channels influence access and support structures, encompassing hospital pharmacies, online pharmacies, retail outlets, and specialty pharmacies that play varying roles in reimbursement coordination and patient education. Finally, treatment settings range from home-based care to hospital-based management and specialty dermatology clinics, shaping service delivery models, adherence supports, and opportunities for remote monitoring. Collectively, these segmentation dimensions should be integrated into clinical development plans, commercial launch strategies, and payer engagement frameworks to ensure alignment with real-world treatment pathways and stakeholder needs.

Region-specific dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory strategy, access pathways, and commercialization approaches

Regional dynamics continue to shape development priorities, regulatory planning, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a mature regulatory environment and established specialty care networks favor rapid uptake of innovative biologics and advanced support services, alongside ongoing emphasis on payer negotiations and formulary placement. Clinician networks and patient advocacy channels in this region frequently drive early adoption patterns for high-efficacy therapies, while reimbursement mechanisms require clear demonstration of long-term benefit.

In Europe, Middle East & Africa, fragmented regulatory frameworks and diverse payer systems necessitate regionally tailored value dossiers and real-world evidence strategies to secure access. Parallel regulatory pathways and heightened health-technology assessment scrutiny often demand comparative effectiveness and cost-effectiveness evidence, prompting manufacturers to plan multi-country data generation and differentiated pricing strategies. In addition, supply-chain constraints in some markets influence distribution choices and the need for local partnership strategies.

Asia-Pacific markets display a heterogeneous mix of rapid adoption in advanced urban centers and variable access across emerging markets. Regulatory timelines and domestic manufacturing policies can influence launch sequencing, and patient populations with distinct genetic or phenotypic characteristics may require targeted clinical evidence. Across all regions, the increasing role of specialty pharmacies, digital engagement tools, and home-based treatment solutions is reshaping patient journeys and requiring manufacturers to craft region-sensitive patient support and commercial models. These regional nuances should guide prioritization of launch resources, evidence generation, and distribution partnerships.

Company-level strategies emphasizing clinical differentiation, manufacturing agility, payer-aligned evidence generation, and patient-centric commercialization in psoriasis therapeutics

Leading pharmaceutical and biotech companies active in psoriasis therapeutics are navigating a complex mix of clinical differentiation, manufacturing demands, and payer engagement. Established biologics developers are intensifying investments in next-generation interleukin-targeting agents and lifecycle management, while smaller biotechs focus on innovative mechanisms of action and biomarker-driven indications. Concurrently, specialty pharmaceutical firms are advancing oral small molecules that emphasize ease of administration and combination strategies to address patient subgroups seeking non-injectable options. Across these varied company profiles, strategic priorities coalesce around demonstrating durable efficacy, improving safety profiles, and optimizing patient experience through delivery and support innovations.

Operationally, companies are strengthening manufacturing agility and partnering with contract development and manufacturing organizations to secure biologics capacity and ensure rapid scale-up for clinical and commercial supply. Commercially, organizations are aligning evidence generation with payer expectations by investing in real-world outcomes research and longitudinal safety monitoring. Collaboration with specialty pharmacies and digital health vendors is increasingly common to support adherence, remote monitoring, and patient education. Mature players often leverage global networks to expedite regulatory filings and market entry, while emerging entrants prioritize niche differentiation, strategic partnerships, and targeted clinical programs to gain footholds in specific patient segments. The combined effect is a competitive environment where therapeutic innovation must be matched by robust supply, evidence, and patient-centric commercialization capabilities.

Actionable strategic priorities for industry leaders to align clinical differentiation, manufacturing resilience, payer engagement, and patient-centric commercialization for durable success

Industry leaders should adopt a multi-pronged strategy that balances scientific investment with pragmatic operations and payer engagement to prosper in the evolving psoriasis landscape. Prioritize development programs that pair clear mechanistic differentiation with robust safety and durability endpoints, and design clinical trials that capture patient-reported outcomes and real-world effectiveness dimensions to support comprehensive value narratives. Simultaneously, commit resources to manufacturing flexibility, including regional capacity and validated alternate suppliers, to reduce exposure to trade policy fluctuations and to support uninterrupted clinical and commercial supply.

Engage early and iteratively with payers and health-technology assessment bodies to align evidence generation with reimbursement expectations, and structure innovative contracting arrangements that share risk and demonstrate outcome linkage. Invest in distribution and patient-support ecosystems by cultivating partnerships with specialty pharmacies and digital health providers that enhance adherence, remote monitoring, and home-based administration capabilities. Finally, implement a regionalized market-entry playbook that tailors regulatory submissions, pricing strategies, and patient engagement to local system characteristics while preserving global evidence coherence. By integrating clinical excellence with operational resilience and payer-centric value demonstration, organizations can create defensible pathways to sustained adoption and meaningful patient outcomes.

Methodology detailing primary expert engagements, secondary evidence triangulation, and scenario-based analyses underpinning strategic and operational conclusions in the report

This research synthesizes a structured review of primary and secondary sources, expert consultations, and qualitative analyses to ensure rigorous and defensible findings. Primary inputs included interviews with clinical thought leaders, payers, supply-chain specialists, and commercial executives who provided context on treatment adoption, reimbursement dynamics, and operational constraints. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, public company disclosures, and technical manufacturing references to corroborate clinical mechanisms, safety considerations, and production realities.

Analytical methods integrated thematic synthesis of qualitative inputs, cross-validation of regulatory and clinical evidence, and scenario-based assessment of supply-chain and policy impacts. The methodology emphasized transparency in data provenance, careful triangulation of diverse information sources, and sensitivity analyses for operational risk factors. Where possible, findings were corroborated with multiple independent sources to reduce bias, and expert reviewers provided validation of clinical interpretations and strategic implications. Limitations are acknowledged; specifically, the analysis focuses on structural, clinical, and operational dynamics rather than quantitative market projections. The approach supports actionable insights for strategic planning, product development prioritization, and evidence generation strategies.

Concluding synthesis highlighting the imperative to integrate scientific innovation, operational resilience, payer-aligned evidence, and patient-centric delivery to realize therapeutic impact

In conclusion, the psoriasis therapeutics landscape offers substantial scientific opportunity coupled with heightened operational and commercial complexity. Advances in biologics and targeted small molecules have raised the standard of care, yet successful translation into sustained patient benefit requires comprehensive strategies that integrate evidence generation, manufacturing resilience, and payer-aligned value demonstration. Stakeholders must recognize that clinical differentiation alone is insufficient without parallel investments in supply-chain agility, patient-centric delivery mechanisms, and real-world evidence programs that substantiate long-term outcomes.

Moving forward, companies that proactively align clinical development with pragmatic access strategies and robust patient support models will be best positioned to navigate regulatory heterogeneity and payer demands. Moreover, organizations that adapt supply networks to mitigate policy and trade risks can secure competitive advantages in launch execution and continuity of supply. Ultimately, a holistic approach that marries scientific innovation with operational excellence and strategic collaborations will drive meaningful improvements in patient care while enabling sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Drugs Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. IL 17 Inhibitors
    • 8.1.2. IL 23 Inhibitors
    • 8.1.3. TNF Inhibitors
  • 8.2. Small Molecules
    • 8.2.1. JAK Inhibitors
    • 8.2.2. PDE4 Inhibitors

9. Psoriasis Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Suspensions
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Foams
    • 9.3.3. Gels
    • 9.3.4. Ointments

10. Psoriasis Drugs Market, by Psoriasis Type

  • 10.1. Erythrodermic Psoriasis
  • 10.2. Guttate Psoriasis
  • 10.3. Inverse Psoriasis
  • 10.4. Nail Psoriasis
  • 10.5. Plaque Psoriasis
  • 10.6. Pustular Psoriasis
  • 10.7. Scalp Psoriasis

11. Psoriasis Drugs Market, by Patient Type

  • 11.1. Adults
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Psoriasis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
  • 12.4. Specialty Pharmacies

13. Psoriasis Drugs Market, by Treatment Setting

  • 13.1. Home-Based Treatment
  • 13.2. Hospital-Based Care
  • 13.3. Specialty Dermatology Clinics

14. Psoriasis Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Psoriasis Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Psoriasis Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Psoriasis Drugs Market

18. China Psoriasis Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Almirall S.A.
  • 19.7. Amgen Inc
  • 19.8. AstraZeneca PLC
  • 19.9. Biogen Inc.
  • 19.10. Boehringer Ingelheim International GmbH
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Dermavant Sciences Ltd.
  • 19.13. Eli Lilly and Company
  • 19.14. Glenmark Pharmaceuticals Ltd.
  • 19.15. Incyte Corporation
  • 19.16. Johnson & Johnson Services, Inc.
  • 19.17. LEO Pharma A/S
  • 19.18. Merck & Co., Inc.
  • 19.19. Novartis AG
  • 19.20. Pfizer Inc.
  • 19.21. Sanofi S.A.
  • 19.22. Sun Pharmaceutical Industries Ltd
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 231. GCC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 235. GCC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 267. G7 PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. G7 PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 271. G7 PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. G7 PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 274. G7 PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 275. G7 PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. G7 PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 279. NATO PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 282. NATO PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 283. NATO PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. NATO PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 286. NATO PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 287. NATO PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. NATO PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)